Zaleplon Capsules

Pharmacological action: Zaleplon is a hypnotic. Its chemical structure is different from benzodiazepines, barbiturates and other known hypnotic drugs. It may exert its pharmacological action by acting on the gamma-aminobutyric acid-benzodiazepine (GABA-BZ) receptor complex. Nonclinical studies have shown that zaleplon can selectively bind to the ω-1 receptor of the α subunit of the brain GABAA receptor complex. The results of the binding test of zaleplon to purified GABAA receptors ((α)1β1γ2[ω-1] and ((α)2β1γ2[ω-2]) showed that it has a low affinity for the above receptors and can preferentially bind to the ω-1 receptor. Toxicological studies: Reproductive toxicity: In the reproductive toxicity test, rats were orally administered zaleplon for 10

Zaleplon

This product is a hard capsule, and the contents are off-white powder or granules.

This product is suitable for the short-term treatment of insomnia with difficulty falling asleep. Clinical research results show that zaleplon can shorten the time it takes to fall asleep, but it has not yet been shown to increase sleep time and reduce the number of awakenings.

Oral, 5-10 mg (1-2 tablets) at a time, taken before bedtime or when having trouble falling asleep. Like all sedative hypnotics, taking zaleplon while awake can cause memory impairment, hallucinations, coordination disorders, and dizziness. For patients with low body weight, the recommended dose is 5 mg (1 tablet) at a time. For elderly patients, diabetics, and patients with mild to moderate liver dysfunction, the recommended dose is 5 mg (1 tablet) at a time. Take only once a night. Continuous medication is limited to 7-10 days. If insomnia is not alleviated after taking the medication for 7-10 days, the doctor should re-evaluate the cause of the patient's insomnia.

After taking zaleplon, you may experience mild headache, drowsiness, dizziness, dry mouth, sweating, anorexia, abdominal pain, nausea and vomiting, fatigue, memory difficulties, dreaminess, depression, tremor, unsteady standing, diplopia, other vision problems, and mental confusion. Other adverse reactions include: 1. After taking zaleplon (10 or 20 mg), short-term memory impairment will occur in about 1 hour. The impairment effect is stronger at the 20 mg dose, but no impairment occurs after 2 hours; 2. After taking zaleplon (10 or 20 mg), there is the expected sedation and psychomotor impairment effect in about 1 hour, but after 2 hours, there is no impairment; 3. Rebound insomnia is dose-dependent. Clinical trials have shown that 5 mg and 10 mg have a significant effect on insomnia.

1. Patients who are allergic to this product are prohibited from using this product. 2. Patients with severe liver and kidney dysfunction are prohibited from using this product. 3. Patients with sleep apnea syndrome are prohibited from using this product. 4. Patients with myasthenia gravis are prohibited from using this product. 5. Patients with severe dyspnea or chest diseases are prohibited from using this product.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

With central nervous system drugs: Ethanol: This product can enhance the damaging effect of ethanol on the central nervous system, but does not affect the pharmacokinetics of ethanol. Imipramine: When this product is used in combination with imipramine, the level of sobriety is reduced, and motor, mental and behavioral abilities are impaired. The interaction is pharmacodynamic, and there is no pharmacokinetic change. Paroxetine: This product has no interaction with paroxetine. Thiodalizine: When this product is used in combination with thiodalizine, the level of sobriety is reduced, and motor, mental and behavioral abilities are impaired. The interaction is pharmacodynamic, and there is no pharmacokinetic change. With enzyme inducing/inhibiting drugs: When used in combination with enzyme inducers such as rifampicin, the Cmax and AUC of this product will be reduced by 4 times. There is no pharmacokinetic interaction when this product is used in combination with diphenhydramine.

Keep sealed.

5 mg

24 months

Shenzhen Haibin Pharmaceutical Co., Ltd.

• Founded in:

  1989-08-22

• Address:

  No. 2003, Shenyan Road, Shatoujiao, Yantian District, Shenzhen

• Tax NO.:

  91440300618855174Y

• Registered Funds:

  700 million yuan

• Website:

  Log in to view

• Email:

  Log in to view